Legendary Director Sidney Lumet Dies of Lymphoma at 86

The death of Sidney Lumet, the award-winning director of historic and legendary films like “Dog Day Afternoon” and “Network” this past Saturday came as a blow to movie-makers everywhere. The iconic filmmaker died in his home in New York City from lymphoma at the age of 86.

Lumet’s career lasted six decades, and he ushered in over 40 films during that time. Among his best known classics were "12 Angry Men" (1957), "Serpico" (1973), "Murder on the Orient Express" (1974), "Dog Day Afternoon" (1975), "Network" (1976), and "The Wiz" (1978).

Famously, Lumet refused to work anywhere other than New York in order to preserve the quality in his craft. That, coupled with his theater-honed background made him very much unlike the typical Hollywood director that one would usually encounter over the past few decades. A product of the Depression-times, he had a sensibility about him that was respected by many and questioned by few.

As he came up in Hollywood, Lumet brought many of the techniques he picked up during his time on stage with him to the big screen. He insisted on heavy rehearsals and bringing in complicated and over-the-top projects in under budget.

In 2005, Lumet was given the Acadamey Award for Lifetime Achievment in recognition of his "brilliant services to screenwriters, performers, and the art of the motion picture."

Lumet’s most recent work was the 2007-released “Before the Devil Knows You’re Dead.”

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap